A survey of preventive measures among BRCA1 mutation carriers from Poland

Clinical Genetics

Volumn 71, Issue 2, 2007, Pages 153-157

  Gronwald, Jacek ^a   Byrski, T ^a   Huzarski, T ^a   Cybulski, C ^a   Stawicka, M ^b   Szwiec, M ^c   Debniak, T ^a   Tulman, A ^d   Sun, P ^d   Oszurek, O ^a   Lubinski, J ^a   Narod, S A ^d  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Cancer Prevention and Epidemiology Center ^*  (Poland)

^c Regional Oncology Center   (Poland)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA1; Breast cancer; Oophorectomy; Ovarian cancer; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST FEEDING; CANCER RISK; CANCER SCREENING; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HEALTH PROMOTION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVARY CANCER; PATIENT COUNSELING; POLAND; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST FEEDING; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; FEMALE; GENES, BRCA1; HETEROZYGOTE; HUMANS; MASTECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; POLAND; QUESTIONNAIRES; RISK FACTORS; RISK REDUCTION BEHAVIOR; TAMOXIFEN;

EID: 33846662012     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2007.00742.x     Document Type: Article

References (24)

1. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1 -mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995: 56: 265-271.
2. Antoniou AC, Pharoah PD, Narod S et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: A combined analysis of 22 population based studies. J Med Genet 2005: 42: 602-603.
3. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003: 72: 1117-1130.
4. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003: 302: 643-646.
5. Eisen A, Lubinski J, Klijn J et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 2005: 23: 7491-7496.
6. Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002: 346: 1609-1615.
7. Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002: 346: 1616-1622.
8. Gronwald J, Byrski T, Huzarski T et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2005: 27: 1-5.
9. Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001: 345: 159-164.
10. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004: 22: 1055-1062.
11. Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004: 22: 2328-2335.
12. Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000: 356: 1876-1881.
13. Gronwald J, Tung N, Foulkes WD et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 2006: 118: 2281-2284.
14. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998: 339: 424-428.
15. Narod SA, Dube MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002: 94: 1773-1779.
16. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004: 292: 1317-1325.
17. Leach MO, Boggis CR, Dixon AK et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 2005: 365: 1769-1778.
18. Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004: 351: 427-437.
19. Jernstrom H, Lubinski J, Lynch HT et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2004: 96: 1094-1098.
20. Gorski B, Cybulski C, Huzarski T et al. Breast cancer predisposing alleles in Poland. Breast Can Res Treat 2005: 92: 19-24.
21. Gorski B, Byrski T, Huzarski T et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000: 66: 1963-1968.
22. Gorski B, Byrski T, Huzarski T et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004: 110: 683-686.
23. Metcalfe KA, Snyder C, Seidel J et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005: 4: 97-103.
24. Brekelmans CT, Seynaeve C, Menke-Pluymers M et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 2006: 17: 391-400.